CRMA-1001

DRUG2 trials

Sponsors

Nchroma Bio Inc., nChroma Bio

Conditions

Chronic Hepaititis BChronic Hepatitis B

Phase 1

A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B

RecruitingNCT07200193

nChroma BioChronic Hepaititis B

Start: 2025-12-22End: 2032-12-31Target: 66Updated: 2026-06-15

A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults with Chronic Hepatitis B

Not yet recruitingCTIS2025-523619-12-00

Nchroma Bio Inc.Chronic Hepatitis B

Target: 10Updated: 2026-02-20